Serum Cystatin C Predicts Mortality in HBV-Related Decompensated Cirrhosis
Table 2
Comparison of the surviving and nonsurviving patients with HBV-DeCi.
Non-surviving patients
Surviving patients
P
(n = 25)
(n = 50)
Age (years)
53.8±12.3
52.3±10.2
0.262
Gender (male/female)
19/6
40/10
0.768
Total protein (g/L)
58.5±9.3
58.9±7.5
0.199
Albumin (g/L)
28.1±5.1
27.9±5.3
0.873
ALT (U/L)
39.0(23.8-49.8)
37.0(21.0-74.0)
0.942
AST (U/L)
56.5(38.5-95.5)
53.0(40.8-86.5)
0.660
Total bilirubin (μmol/L)
96.0(74.8-247.3)
101.0(51.0-180.0)
0.261
Serum Cr (mmol/L)
97.0(69.0-125.5)
66.5(58.0-83.0)
0.002
INR
1.79±0.49
1.59±0.30
0.040
MELD score
20.5(17.9-22.7)
15.2(13.0-17.8)
<0.001
Child-Pugh score
10.0(9.0-11.0)
10.0(9.0-10.0)
0.376
Cystatin C (mg/L)
1.52(1.12-2.12)
0.98(0.87-1.18)
<0.001
Data are expressed as n, mean ± SD, or median (interquartile range). ALT, alanine aminotransferase; AST, aspartate aminotransferase; Cr, creatinine; INR, international normalized ratio; MELD score, model for end-stage liver disease score.
